January 14, 2025Healthcare
News
December 16, 2024Healthcare
J-TEC and Shiven Biotech Sign a Distributor Agreement Concerning the Sale of Cultured Human Tissue for Research Use[Japan Tissue Engineering]
December 13, 2024Healthcare
Teijin Pharma Limited Applies for Manufacturing and Marketing Approval in Japan for New Hypoparathyroidism Treatment[Teijin Pharma] (PDF: 303.2 KB)
December 5, 2024Healthcare
Sysmex and J-TEC Sign a Basic Agreement to Advance Manufacturing Capabilities for Regenerative Medicine and Cell Therapy[Japan Tissue Engineering]
October 31, 2024Healthcare
Teijin and Hilleman Laboratories to Expand Business in Asia-Pacific via Strategic Partnership to Promote CDMO Services in Cell and Gene Therapy[Teijin] (PDF: 162.0 KB)
June 6, 2024Healthcare
CureApp, Inc. and Teijin Pharma Sign Agreement for Joint Marketing and Sales of Prescription Digital Therapeutic App for Hypertension[Teijin Pharma] (PDF: 296.3 KB)
May 27, 2024Healthcare
SYNFOLIUM®, a Novel Cardiovascular Surgical Patch, to Be Marketed in Japan on June 12[Teijin] (PDF: 436.7 KB)
April 10, 2024Healthcare
Teijin Pharma Grants Global Exclusive License to Bioprojet to Develop a New Orexin Receptor 2 Agonist Investigational Candidate for Narcolepsy[Teijin Pharma] (PDF: 133.2 KB)
April 1, 2024Healthcare
Axcelead, Inc. and Teijin Jointly Established Axcelead Tokyo West Partners, Inc., the Drug Discovery Support Service JV[Teijin] (PDF: 161.5 KB)
March 28, 2024Healthcare
Research Suggests Inulin Intake Reduces Risk of Death from Novel Coronavirus Infection in a Hamster Model[Teijin] (PDF: 235.9 KB)
February 13, 2024Healthcare
Teijin and Axcelead, Inc. to Determine the Name of Drug Discovery Research JV[Teijin] (PDF: 143.2 KB)
November 29, 2023HealthcareIR
Notice Concerning a Decision on the Licensing Agreement related to the Three Hormone Therapy Drugs for Rare Endocrine Diseases[Teijin] (PDF: 163.8 KB)
October 18, 2023Healthcare
Teijin to Enhance BARLEYmax™ Super Barley Marketing for Bakery Applications in Europe[Teijin] (PDF: 215.2 KB)
September 6, 2023Healthcare
Teijin to Boost BARLEYmax™ Super Barley Marketing in Europe[Teijin] (PDF: 212.6 KB)
August 30, 2023Healthcare
Research Suggests Human Immune Function and Viral Infection Suppression Can Be Enhanced by Bacillus subtilis BN[Teijin Meguro Institute] (PDF: 224.8 KB)
July 12, 2023Healthcare
SYNFOLIUM®: Novel Cardiovascular Surgical Patch Receives Manufacturing and Marketing Approval in Japan[Teijin, Teijin Medical Technologies] (PDF: 458.9 KB)
July 3, 2023Healthcare
Teijin and Axcelead, Inc., to Establish Drug Discovery Research Joint Venture[Teijin] (PDF: 136.5 KB)
April 21, 2023Healthcare
Teijin, J-TEC and Resilience US, Inc. Form Business Alliance to Spur Development of New Regenerative Medicine Technologies[Teijin,Japan Tissue Engineering] (PDF: 189.9 KB)
March 28, 2023Healthcare
Teijin, Mediridge Co., Ltd. and TFBS Bioscience Inc. to Supply Raw Materials for Regenerative Medicine Development and Manufacture[Teijin] (PDF: 237.2 KB)
March 27, 2023Healthcare
A Submission for an Marketing Approval of Cardiovascular Patch is Filed in Japan[Teijin] (PDF: 227.3 KB)
March 6, 2023Healthcare
Teijin Pharma Grants Global Exclusive License for Investigational Small Molecule Candidate in Kidney Disease[Teijin Pharma] (PDF: 115.5 KB)
February 20, 2023Healthcare
Teijin and Axcelead, Inc. to Establish Drug Discovery Research JV[Teijin] (PDF: 133.5 KB)
January 30, 2023Healthcare
Teijin Pharma to Launch Japan-market Sales of Abaloparatide Acetate for Osteoporosis [Teijin Pharma] (PDF: 189.2 KB)
October 3, 2022Healthcare
Teijin Launches Teijin Meguro Institute to Strengthen Functional Food Ingredients Business[Teijin] (PDF: 130.7 KB)
September 27, 2022Healthcare
Teijin, J-TEC, Mitsui Fudosan Co., Ltd. and National Cancer Center to Establish Regenerative Medicine Platform[Teijin,Japan Tissue Engineering] (PDF: 432.2 KB)
September 5, 2022Healthcare
Teijin Pharma Receives Additional Approval in Japan for Abaloparatide Acetate as Treatment for Osteoporosis[Teijin Pharma] (PDF: 153.2 KB)
June 13, 2022Healthcare
Teijin to Launch BARLEYmax™ Super Barley in Europe[Teijin] (PDF: 212.7 KB)
May 17, 2022Healthcare
Osaka Medical and Pharmaceutical University, Fukui Tateami Co., Ltd. and Teijin Achieve Primary Endpoint in Cardiovascular Patch Clinical Trial[Teijin] (PDF: 195.6 KB)
April 18, 2022Healthcare
Teijin and JCR Pharmaceuticals Co., Ltd. Cease JTR-161 Dental Pulp Stem Cell Research[Teijin] (PDF: 137.8 KB)
April 5, 2022Healthcare
Iktos and Teijin Pharma to Co-Develop New Technology for Small Molecule Drug Discovery[Teijin Pharma] (PDF: 183.8 KB)
March 9, 2022Healthcare
Teijin’s BARLEYmax™ Super Barley Adopted by Taiwan MOS Burger[Teijin] (PDF: 226.8 KB)
February 1, 2022Healthcare
Anti-Tau Antibody created by Teijin Pharma and developed by Merck & Co., Inc., Kenilworth NJ USA Enters Clinical Development[Teijin Pharma] (PDF: 112.5 KB)
October 29, 2021Healthcare
Teijin Nakashima Medical to Acquire Otsuka Group Company’s Spine and Trauma Business[Teijin,Teijin Nakashima Medical] (PDF: 160.6 KB)
June 23, 2021Healthcare
Teijin Receives Additional Approval in Japan for Merz’s Xeomin® Botulinum Toxin Type A[Teijin Pharma] (PDF: 184.2 KB)
June 1, 2021Healthcare
Industry-Academia Collaborated Microstructure Spine-Fusing Device Now Covered Under Japanese National Health Insurance[Teijin Nakashima Medical] (PDF: 179.4 KB)
April 23, 2021Healthcare
Teijin and Jolly Good Inc. to Jointly Develop VR-based Depression-treatment System[Teijin Pharma] (PDF: 178.6 KB)
April 1, 2021HealthcareIR
Notice Regarding Completion of Transfer of Japan Sales of Type 2 Diabetes Treatments[Teijin] (PDF: 82.4 KB)
March 23, 2021Healthcare
Teijin to Commence Manufacture and Sale in Japan of Abaloparatide Acetate as Treatment for Osteoporosis[Teijin Pharma] (PDF: 177.3 KB)
February 26, 2021HealthcareIR
Notice Regarding Execution of Asset Transfer Agreement for Transfer of Japan Sales, Intellectual Properties, and Manufacturing and Marketing Approval of Type 2 Diabetes Treatments (Nesina®, Liovel®, Inisync®, and Zafatek®)[Teijin] (PDF: 206.4 KB)
January 27, 2021Healthcare
Targeted Number of Subjects Registered for Cardiovascular Patch Clinical Trial[Teijin] (PDF: 151.5 KB)
December 18, 2020Healthcare
Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration[Teijin Pharma] (PDF: 142.9 KB)
December 4, 2020Healthcare
Teijin Starts Exclusive Sales of Merz’s Xeomin® Botulinum Toxin Type A in Japan[Teijin Pharma] (PDF: 169.0 KB)
August 7, 2020Healthcare
Teijin and CoreTissue BioEngineering Agree on Alliance to Mass Produce Artificial Ligament[Teijin] (PDF: 188.9 KB)
June 29, 2020Healthcare
Teijin Receives Marketing Approval for Merz’s Xeomin® Botulinum Toxin Type A in Japan[Teijin Pharma] (PDF: 210.7 KB)
May 27, 2020Healthcare
Teijin Applies for Approval to Manufacture and Sell Abaloparatide Acetate as Osteoporosis Treatment in Japan[Teijin Pharma] (PDF: 176.0 KB)
April 6, 2020Healthcare
Teijin to invest in U.S. Venture-capital Fund[Teijin] (PDF: 103.5 KB)
February 27, 2020Healthcare
Teijin Launches Super Barley in Asia[Teijin]
January 15, 2020Healthcare
Teijin Home Healthcare Limited to Change its Name[Teijin Pharma, Teijin Home Healthcare]
January 9, 2020Healthcare